The course of disseminated intravascular coagulation is predicted by changes in thrombin???antithrombin III complex levels???is there any difference between treatment with standard heparin or low-molecular-weight heparin?

1991 ◽  
Vol 2 (5) ◽  
pp. 623-628 ◽  
Author(s):  
H. Asakura ◽  
H. Jokaji ◽  
M. Saito ◽  
C. Uotani ◽  
I. Kumabashiri ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Disseminated Intravascular Coagulation ◽  
Low Molecular Weight Heparin ◽  
Antithrombin Iii ◽  
Low Molecular Weight ◽  
Intravascular Coagulation ◽  
Thrombin Antithrombin Iii Complex

Human Urinary Soluble Thrombomodulin (MR-33) Improves Disseminated Intravascular Coagulation without Affecting Bleeding Time in Rats: Comparison with Low Molecular Weight Heparin

1997 ◽  
Vol 77 (04) ◽  
pp. 789-795 ◽  
Author(s):  
Yasuo Takahashi ◽  
Yoshitaka Hosaka ◽  
Kazunori Imada ◽  
Takehiro Adachi ◽  
Hiromi Niina ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Disseminated Intravascular Coagulation ◽  
Low Molecular Weight Heparin ◽  
Bleeding Time ◽  
Low Molecular Weight ◽  
Soluble Thrombomodulin ◽  
Intravascular Coagulation ◽  
Significant Prolongation ◽  
Dose Dependent Fashion ◽  
Dose Dependent

SummaryWe compared the antithrombotic and hemorrhagic effects of naturally existing human urinary soluble thrombomodulin (MR-33) with those of low molecular weight heparin (LMW-heparin) in rats. In in vitro experiments, MR-33 prolonged APTT in a dose-dependent fashion; its effect in this respect was as potent as that of LMW-heparin, but it was less potent than unfractionated heparin (UF-heparin). MR-33 was effective on endotoxin- or thromboplastin-induced disseminated intravascular coagulation (DIC) in rats. In both DIC models, infusion of MR-33 improved hematological abnormalities compatible with DIC in a dose-dependent fashion without excessive prolongation effect on APTT. Although LMW-heparin and UF-heparin also improved both DIC models, excessive prolongation of APTT was observed at high doses. It is well-known that the excessive prolongation of APTT with antithrombotic drugs like heparins is an index for hemorrhage, which is a major side effect in the treatment of DIC. We therefore further compared the antithrombotic (Benefit: dose required for 50% inhibition of fibrinogen decrease: ED50) and hemorrhagic (Risk: minimum dose required for significant prolongation of bleeding time) effects of MR-33 and LMW-heparin in the thromboplastin-induced DIC model. As a result, Benefit-Risk ratio was 1:27 for MR-33 and 1:3 for LMW heparin. These results indicate that MR-33 may be a clinically useful antithrombotic agent with reduced risk for hemorrhage compared with LMW-heparin.

Effects of low molecular weight heparin on a severely antithrombin III-decreased diseminated intravascular coagulation model in rabbits

1995 ◽  
Vol 80 (5) ◽  
pp. 391-398 ◽  
Author(s):  
Shigeki Tazawa ◽  
Kiyoshi Ichikawa ◽  
Keiko Misawa ◽  
Juichi Fukuyama ◽  
Shuichiro Hamano ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Antithrombin Iii ◽  
Low Molecular Weight ◽  
Intravascular Coagulation
Sign in / Sign up

Export Citation Format

Share Document